The global vaccine market is expected to achieve $34 billion in sales by 2012. With an estimated annual growth rate of 14% during the next five years, vaccines will be the fastest-growing therapeutic area, even outpacing oncology.
The recently renewed interest in the vaccine sector is attributed to advances in technology, federal liability protection for developers, increasing global demand, and premium pricing for new products.
This special report focuses on the market leaders for vaccines as well as the products in development anticipated to head this therapeutic area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of vaccine prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of vaccine medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the vaccine field.